4.3 Article

Indomethacin increases severity of Clostridium difficile infection in mouse model

Journal

FUTURE MICROBIOLOGY
Volume 13, Issue 11, Pages 1271-1281

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/fmb-2017-0311

Keywords

antibiotic-associated CDI; C; difficile infection severity; indomethacin; NSAID; prostaglandins

Categories

Funding

  1. Fondo Nacional de Ciencia y Tecnologia de Chile (FONDECYT) [1151025]
  2. Fondo de Fomento al Desarrollo Cientifico y Tecnologico (FONDEF) [ID16|10038]
  3. NIH [TR001723, AI121796]
  4. Vanderbilt Digestive Diseases Research Center NIH [DK058404]
  5. CAPES [BEX 9179/11-9]
  6. [CONICYT 21161395]

Ask authors/readers for more resources

Aim: To evaluate the effect on the nonsteroidal anti-inflammatory drug indomethacin on Clostridium difficile infection (CDI) severity. Materials & methods: Indomethacin was administered in two different mouse models of antibiotic-associated CDI in two different facilities, using a low and high dose of indomethacin. Results: Indomethacin administration caused weight loss, increased the signs of severe infection and worsened histopathological damage, leading to 100% mortality during CDI. Indomethacin-treated, antibiotic-exposed mice infected with C. difficile had enhanced intestinal inflammation with increased expression of KC, IL-1 and IL-22 compared with infected mice unexposed to indomethacin. Conclusion: These results demonstrate a negative impact of nonsteroidal anti-inflammatory drugs on antibiotic-associated CDI in mice and suggest that targeting the synthesis or signaling of prostaglandins might be an approach to ameliorating the severity of CDI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available